Corrigendum: Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes

Tracy Gasperetti; Tessa Miller; Feng Gao; Jayashree Narayanan; Elizabeth R Jacobs; Aniko Szabo; George N Cox; Christie M Orschell; Brian L Fish; Meetha Medhora

doi:10.3389/fphar.2021.741485

Corrigendum: Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes

Front Pharmacol. 2021 Aug 25:12:741485. doi: 10.3389/fphar.2021.741485. eCollection 2021.

Authors

Tracy Gasperetti¹, Tessa Miller¹, Feng Gao¹, Jayashree Narayanan¹, Elizabeth R Jacobs^{2

3

4

5}, Aniko Szabo⁶, George N Cox⁷, Christie M Orschell⁸, Brian L Fish¹, Meetha Medhora^{1

2

3

4

5}

Affiliations

¹ Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
² Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.
³ Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, United States.
⁴ Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States.
⁵ Department of Veterans Affairs, Research Service, Zablocki VAMC, Milwaukee, WI, United States.
⁶ Institute for Health and Equity, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States.
⁷ Bolder BioTechnology Inc., Boulder, CO, United States.
⁸ Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

Abstract

[This corrects the article DOI: 10.3389/fphar.2021.634477.].

Keywords: acute radiation syndrome; delayed effects of acute radiation exposure; hematopoietic growth factor; lisinopril; mitigation; polypharmacy; radiation pneumonitis; supportive care.

Publication types

Published Erratum

Grants and funding

I01 BX003833/BX/BLRD VA/United States